Influence of immunogenicity on the efficacy of long-term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Arstikyte, Inesa ^a   Kapleryte, Giedre ^a   Butrimiene, Irena ^a   Venalis, Algirdas ^a   Shi, Guixiu ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b State Research Institute Centre for Innovative Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIIDIOTYPIC ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ANTIBODY BLOOD LEVEL; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BLOOD SAMPLING; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; TREATMENT RESPONSE; VISUAL ANALOG SCALE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929358899     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/604872     Document Type: Article

References (37)

1. E. L. Kneepkens, C. L. M. Krieckaert, D. van der Kleij et al., "Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of followup, " Annals of the Rheumatic Diseases, 2014.
2. E. L. Kneepkens, J. C.-C. Wei, M. T. Nurmohamed et al., "Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up, " Annals of the Rheumatic Diseases, vol. 74, no. 2, pp. 396-401, 2015.
3. M. K. de Vries, G. J. Wolbink, S. O. Stapel et al., "Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation, " Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 133-134, 2007.
4. D. Mazilu, D. Opriş, C. Gainaru et al., "Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treatedwith biologic agentswho experience inadequate response while being on a stable biologic treatment, " BioMed Research International, vol. 2014, Article ID 702701, 8 pages, 2014.
5. C. C. Mok, D. van der Kleij, and G. J.Wolbink, "Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases, " Clinical Rheumatology, vol. 32, no. 10, pp. 1429-1435, 2013.
6. G. M. Bartelds, C. L. M. Krieckaert, M. T. Nurmohamed et al., "Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up, " The Journal of the American Medical Association, vol. 305, no. 14, pp. 1460-1468, 2011.
7. M. Hoshino, T. Yoshio, S. Onishi, and S. Minota, "Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis, " Modern Rheumatology, vol. 22, no. 4, pp. 532-540, 2012.
8. M. K. de Vries, I. E. van der Horst-Bruinsma, M. T. Nurmohamed et al., "Immunogenicity does not influence treatment with etanercept in Patients with ankylosing spondylitis, " Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 531-535, 2009.
9. R. K. Dore, S. Mathews, J. Schechtman et al., "The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis, " Clinical and Experimental Rheumatology, vol. 25, no. 1, pp. 40-46, 2007.
10. V. C. Pérez-Guijo, A. R. Cravo, M. D. C. Castro, P. Font, E. Muñoz-Gomariz, and E. Collantes-Estevez, "Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis, " Joint Bone Spine, vol. 74, no. 3, pp. 254-258, 2007.
11. D. Mulleman, F. Lauféron, D. Wendling et al., "Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study, " Arthritis Research andTherapy, vol. 13, no. 3, article R82, 2011.
12. M. Breban, P. Ravaud, P. Claudepierre et al., "Maintenance of infliximab treatment in ankylosing spondylitis: results of a oneyear randomized controlled trial comparing systematic versus on-demand treatment, " Arthritis and Rheumatism, vol. 58, no. 1, pp. 88-97, 2008.
13. P. D. Sampaio-Barros, L. T. L. Costallat, M. B. Bertolo, J. F. M. Neto, and A. M. Samara, "Methotrexate in the treatment of ankylosing spondylitis, " Scandinavian Journal of Rheumatology, vol. 29, no. 3, pp. 160-162, 2000.
14. R.N.Maini, F. C. Breedveld, J. R. Kalden et al., "Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, " Arthritis & Rheumatism, vol. 41, no. 9, pp. 1552-1563, 1998.
15. P. E. Lipsky, D. M. F. M. van der Heijde, E. W. St. Clair et al., "Infliximab and methotrexate in the treatment of rheumatoid arthritis, "The New England Journal ofMedicine, vol. 343, no. 22, pp. 1594-1602, 2000.
16. E. W. St.Clair, C. L. Wagner, A. A. Fasanmade et al., "The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, " Arthritis and Rheumatism, vol. 46, no. 6, pp. 1451-1459, 2002.
17. A. Arora, A. Mahajan, D. Spurden, H. Boyd, and D. Porter, "Long-term drug survival of tnf inhibitor therapy in RA patients: a systematic review of European national drug registers, " International Journal of Rheumatology, vol. 2013, Article ID 764518, 9 pages, 2013.
18. M. Fabbroni, L. Cantarini, F. Caso et al., "Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice, " Mediators of Inflammation, vol. 2014, Article ID 862969, 7 pages, 2014.
19. S. Garcês, J. Demengeot, and E. Benito-Garcia, "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a metaanalysis, " Annals of the Rheumatic Diseases, vol. 72, no. 12, pp. 1947-1955, 2013.
20. G. J. Wolbink, M. Vis, W. Lems et al., "Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, " Arthritis and Rheumatism, vol. 54, no. 3, pp. 711-715, 2006.
21. N. K. Bender, C. E. Heilig, B. Dröll, J. Wohlgemuth, F.-P. Armbruster, and B. Heilig, "Immunogenicity, efficacy and adverse events of adalimumab in RA patients, " Rheumatology International, vol. 27, no. 3, pp. 269-274, 2007.
22. S. M. D. Pan, S. Dehler, A. Ciurea, Z. Hans-Rudolf, C. Gabay, and A. Finckh, "Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis, " Arthritis Care and Research, vol. 61, no. 5, pp. 560-568, 2009.
23. R. N. Jois, J. Leeder, A. Gibb et al., "Low-dose infliximab treatment for ankylosing spondylitis-clinically-and cost-effective, " Rheumatology, vol. 45, no. 12, pp. 1566-1569, 2006.
24. I.De La Torre, L. Valor, J. C.Nieto, M.Montoro, and L. Varreno, "Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sctional study, " Reumatología Clínica, vol. 10, no. 2, pp. 101-104, 2014.
25. I. Arštikyte and I. Butrimiene, "Lietuvos reumatiniH ligH biologines terapijos duomenH baze: 2007-2013 metH veiklos ataskaita, " Vilniaus Reumatologijos Seminarai, vol. 1, no. 8, pp. 46-53, 2014.
26. P. Putrik, S. Ramiro, T. K. Kvien et al., "Inequities in access to biologic and syntheticDMARDs across 46 European countries, " Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 198-206, 2014.
27. A. M. van Gestel, M. L. L. Prevoo, M. A. van't Hof, M. H. van Rijswijk, L. B. A. van de Putte, and P. L. C. M. van Riel, "Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, " Arthritis & Rheumatism, vol. 39, no. 1, pp. 34-40, 1996.
28. C.Castillo-Gallego, S. Z.Aydin, andH.Marzo-Ortega, "Clinical utility of the new ASAS criteria for spondyloarthritis and the disease activity score, " Current Rheumatology Reports, vol. 13, no. 5, pp. 395-401, 2011.
29. Promonitor-ADA, Promonitor-ETA, Promonitor-INF description of performing assays, provided by Proteomica company with kits.
30. D. Pascual-Salcedo, C. Plasencia, S. Ramiro et al., "Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, " Rheumatology, vol. 50, no. 8, pp. 1445-1452, 2011.
31. C. Plasencia, D. Pascual-Salcedo, S. García-Carazo et al., "The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients, " Arthritis Research and Therapy, vol. 15, no. 4, article R79, 2013.
32. C. Plasencia, D. Pascual-Salcedo, L. Nuño et al., "Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab, " Annals of the Rheumatic Diseases, vol. 71, no. 12, pp. 1955-1960, 2012.
33. P. J. Anderson, "Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles, " Seminars in Arthritis and Rheumatism, vol. 34, no. 5, pp. 19-22, 2005.
34. A. van derMaas, W. Kievit, B. J. F. van denBemt, F. H. J. van den Hoogen, P. L. van Riel, and A. A. den Broeder, "Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study, " Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1849-1854, 2012.
35. G. Tenga, V. Goëb, T. Lequerré et al., "A3mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs, " Joint Bone Spine, vol. 78, no. 1, pp. 50-55, 2011.
36. R. D. Inman and W. P. Maksymowych, "A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis, " Journal of Rheumatology, vol. 37, no. 6, pp. 1203-1210, 2010.
37. B. Mörck, R. Pullerits, M. Geijer, T. Bremell, and H. Forsblad-D'Elia, "Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study, " Mediators of Inflammation, vol. 2013, Article ID 289845, 9 pages, 2013.